The affordable Motorola Moto G for 2025 looks attractive and has impressive battery life, but it barely improves upon last year's model. The Moto G doesn’t look like a cheap phone. Its thin ...
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...
Body Dimensions 163.8 x 75 x 8.3 mm (6.45 x 2.95 x 0.33 in) ...
Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up ...
Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...
How do we bring equality to the world? That's a question being debated in the rarefied air of Davos, Switzerland, as billionaires and less wealthy movers and shakers gather at the World Economic ...
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine … ...
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities ...
Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 66% phase transition success rate ...
Facilities for Regeneron Canada in thriving Mississauga/GTA biotech hub signal its growth and readiness to bring more of its life-transforming innovative medicines for serious diseases to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback